English, Article edition: Dosing Patterns of Anti-TNF Therapy in Patients with Rheumatoid Arthritis in a Managed Care Setting Karen Stockl; Manal Jarrar; Neeta Tandon

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/46404
Physical Description
  • article
Language
  • English

Edition details

Title
  • Dosing Patterns of Anti-TNF Therapy in Patients with Rheumatoid Arthritis in a Managed Care Setting
Author
  • Karen Stockl
  • Manal Jarrar
  • Neeta Tandon
Physical Description
  • article
Notes
  • Objective: To characterize the dose administration patterns of tumor necrosis factor (TNF) inhibitors for the treatment of rheumatoid arthritis (RA) within a managed care organization (MCO). Methods: Patients with RA who received either infliximab or etanercept between 1 January 2001 and 31 May 2002 were identified using MCO pharmacy and medical claims. Prescribers were asked to send copies of the identified patients Results: 1869 patients were potentially eligible and 936 of these could be linked to prescribers. A total of 457 of 936 (49%) requested charts were obtained. Of the 369 eligible patients, 164 received infliximab (44%) and 205 received etanercept (56%). The mean first doses ordered of infliximab and etanercept were 3.5 +- 0.6 mg/​kg and 27.9 +- 24.2mg, respectively. Subsequent doses ordered were 4.2 +- 1.4 mg/​kg and 25.7 +- 13.9mg, respectively. Overall, 67% of infliximab infusions used less than or equal to the expected number of vials if administered at 3 mg/​kg. The estimated mean annual medication cost per patient (2004 values) was determined to be $US13 Conclusion: The majority of TNF inhibitor doses were within recommended ranges. Although infliximab can be administered at doses up to 10 mg/​kg, the majority of infliximab infusions were administered at less than or equal to the number of vials expected for a 3 mg/​kg dose (the minimum recommended dose). While these results indicate that a large-scale initiative to improve prescribing of TNF inhibitors may not be needed, a further understanding of the factors that lead to prescribing of high doses of TNF inhibitors might be warranted.
  • Prescribing, Rheumatoid-arthritis, Tumour-necrosis-factor-antagonists
  • RePEc:wkh:dmhout:v:12:y:2004:i:3:p:189-196
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment